R147
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 68
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- P53_PATHWAY+0.310
- ESTROGEN_RESPONSE_EARLY+0.190
- IL6_JAK_STAT3_SIGNALING+0.180
- UV_RESPONSE_UP+0.180
- MYOGENESIS+0.160
- WNT_BETA_CATENIN_SIGNALING+0.160
- ESTROGEN_RESPONSE_LATE+0.150
- NOTCH_SIGNALING+0.140
- XENOBIOTIC_METABOLISM+0.130
- APICAL_JUNCTION+0.120
Top 10 suppressed
- PROTEIN_SECRETION-0.360
- MYC_TARGETS_V1-0.290
- ANDROGEN_RESPONSE-0.280
- G2M_CHECKPOINT-0.280
- E2F_TARGETS-0.230
- MTORC1_SIGNALING-0.220
- UNFOLDED_PROTEIN_RESPONSE-0.210
- SPERMATOGENESIS-0.190
- COMPLEMENT-0.160
- DNA_REPAIR-0.120
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 62a2cbf8-51be-469b-978c-bdf386e0d651 | — | — | 0.791 |
| 2 | MDT-AP-1336 | Med | Medulloblastoma | 0.765 |
| 3 | 8f518c0d-42e0-4418-bb48-f69b32446b46 | — | — | 0.742 |
| 4 | AUR-AER6-TTM10-A-1-1-R-A742-41 | — | C | 0.740 |
| 5 | SRR23303751 | — | — | 0.738 |
| 6 | 1c3d6580-0dc8-4346-a4f7-0bb404d4a245 | — | — | 0.737 |
| 7 | fee5651d-3ac9-474a-84da-4fd0ce06f341 | — | — | 0.732 |
| 8 | R168 | — | — | 0.731 |
| 9 | TCGA-A7-A425-01A-11R-A24H-07 | — | A | 0.730 |
| 10 | d406bb03-1a9a-4aa3-a1a8-4de5478b4701 | — | — | 0.729 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 21 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| P53_PATHWAY | 0.310 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.190 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.180 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.180 | Idelalisib | — uncovered |
| MYOGENESIS | 0.160 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.160 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.150 | Idelalisib | — uncovered |
| NOTCH_SIGNALING | 0.140 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.130 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.120 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.110 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.110 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.100 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.100 | Remibrutinib | — uncovered |
| MYC_TARGETS_V2 | 0.080 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.080 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.080 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.030 | Temsirolimus | — uncovered |
| APOPTOSIS | 0.030 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.030 | Remibrutinib | — uncovered |